Cellectar Biosciences, Inc.
CLRB
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies; Phase 2B cliā¦ read more
Healthcare
Biotechnology
20 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$2.59
Price0.00%
$0.00
1Y
Price
Market Cap
$20.694m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow MarginRevenue
$0.00
-
1y CAGR-
3y CAGR-
5y CAGREarnings
-$20.841m
+4.4%
1y CAGR+17.1%
3y CAGR+4.2%
5y CAGREPS
-$7.38
+11.6%
1y CAGR+50.6%
3y CAGR+43.5%
5y CAGRBook Value
$4.717m
$11.120m
Assets$6.403m
Liabilities$1.529m
DebtDebt to Assets
13.8%
-0.1x
Debt to EBITDAFree Cash Flow
-$18.590m
+19.6%
1y CAGR+9.2%
3y CAGR-0.7%
5y CAGRNo items found.
Press Releases
Statements and updates from the company